Plain-English translation of NCT05438043 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This is a long-term extension study for patients with multiple myeloma (a type of blood cancer) who have been doing well on in earlier clinical trials. The purpose is to let patients continue receiving after their original study ends, either alone or combined with other standard cancer medications. Researchers will continue to monitor your safety and how well the treatment is working.
Once a patient shows benefit from a new cancer treatment during a clinical trial, it's important to keep that treatment available to them while the trial formally ends. This study fills that gap by providing ongoing access and collecting important long-term safety information.
You will continue to receive on a 28-day cycle either as an intravenous infusion or as an injection under the skin (and you can switch between these options if you prefer). Depending on what worked best in your earlier study, you may receive the medication alone or combined with other standard cancer drugs like , , or . You will have regular visits with your research team to monitor how well the treatment is working and to check for any side effects.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
United States